Literature DB >> 26824707

Correction: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.

Geraldine Dominiak-Felden, Corrado Gobbo, François Simondon.   

Abstract

Entities:  

Year:  2016        PMID: 26824707      PMCID: PMC4732785          DOI: 10.1371/journal.pone.0148665

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


× No keyword cloud information.
The image for Fig 1 is incorrect. Please see the correct Fig 1 here.
Fig 1

Incidence of genital warts per 100 000 individuals (dashed line: females; solid line: males) and qHPV vaccine uptake in individuals aged 16–22 years (A), 23–30 years (B), 31–40 years (C) and 41–59 years (D) affiliated to the MLOZ sick fund (Belgium) between 2006 and 2013 (standardised estimates).

There are errors in the fourth row of Table 2. Please see the corrected Table 2 here.
Table 2

Characteristics of the vaccine effectiveness study population as a function of their vaccination status.

Vaccination statusnAge* at 1st dose (years)Age* end of study (years)Number with GWs (%)Age* 1st GWs episode (years)
Unvaccinated63 180-20.2244 (0.39)20.1
1 dose4 02015.820.116 (0.21)19.1
2 doses3 587
3 doses35 79214.719.714 (0.04)19.1
3 doses (as per schedule)24 79114.719.912 (0.05)19.3

*Median age

*Median age There is an error in the third sentence of the last paragraph of the Results section. The correct sentence is: In this second sensitivity analysis, the GWs IR was 113.9 (95%CI: 101.3–128.1) per 100,000 person-years in the non-qHPV vaccine group vs 14.2 (95% CI: 8.8; 22.8) per 100,000 person-years among women fully vaccinated with qHPV vaccine.
  1 in total

1.  Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.

Authors:  Geraldine Dominiak-Felden; Corrado Gobbo; François Simondon
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.